Table 1.
(a)–(d): HLA class-I (A, B, and Cw) phenotypes and HLA-DRB1* genotypes in patients affected by AICU and in the control group.
| Control group | CIU AICU group | P | |
| (n = 200) | (n = 69) | ||
| HLA-A | |||
| (phenotype carrier) | |||
| 1 | 21.0% | 23.2% | NS* |
| 2 | 48.5% | 52.2% | NS |
| 3 | 18.5% | 24.6% | NS |
| 9 | 0% | 0% | NS |
| 10 | 0.5% | 0% | NS |
| 11 | 13.0% | 4.3% | .046 |
| 23 | 6.0% | 2.9% | NS |
| 24 | 32.5% | 26.1% | NS |
| 25 | 2.5% | 7.2% | NS |
| 26 | 8.0% | 5.8% | NS |
| 28 | 0.5% | 4.3% | NS |
| 29 | 2.0% | 2.9% | NS |
| 30 | 7.5% | 2.9% | NS |
| 31 | 6.5% | 2.9% | NS |
| 32 | 8.0% | 5.8% | NS |
| 33 | 4.5% | 5.8% | NS |
| 34 | 0 % | 0 % | NS |
| 35 | 0 % | 0 % | NS |
| 37 | 0 % | 0 % | NS |
| 40 | 0 % | 0 % | NS |
| 43 | 0 % | 0 % | NS |
| 66 | 0.5% | 0 % | NS |
| 68 | 9.5% | 11.6% | NS |
| 69 | 0 % | 2.9% | NS |
| 74 | 0 % | 0 % | NS |
| (a) | |||
| HLA-B | Control group | CIU AICU | P |
| (phenotype carrier) | (n = 200) | group (n = 69) | |
| 5 | 0% | 0 % | NS |
| 7 | 13.5% | 11.6% | NS |
| 8 | 13.5% | 5.8% | NS |
| 12 | 0% | 0% | NS |
| 13 | 9.5% | 0% | .005 |
| 14 | 1.5% | 0 % | NS |
| 15 | 2.0% | 0 % | NS |
| 16 | 0.5% | 0 % | NS |
| 17 | 2.0% | 1.4% | NS |
| 18 | 17.0% | 23.2% | NS |
| 21 | 0 % | 0 % | NS |
| 22 | 0 % | 0 % | NS |
| 23 | 0 % | 1.4% | NS |
| 27 | 6.0% | 7.2% | NS |
| 35 | 29.0% | 24.6% | NS |
| 37 | 3.0% | 4.3% | NS |
| 38 | 4.5% | 4.3% | NS |
| 39 | 8.0% | 4.3% | NS |
| 40 | 2.5% | 0 % | NS |
| 41 | 0.5% | 4.3% | NS |
| 42 | 0 % | 0 % | NS |
| 44 | 13.0% | 29.0% | 0.002 |
| 45 | 1.0% | 1.4% | NS |
| (b) | |||
| HLA-B | Control group | CIU AICU | P |
| (phenotype carrier) | (n = 200) | group (n = 69) | |
| 46 | 0% | 0% | NS |
| 47 | 1.0% | 1.4% | NS |
| 49 | 7.5% | 7.2% | NS |
| 50 | 6.0% | 1.4% | NS |
| 51 | 20.5% | 23.2% | NS |
| 52 | 1.0% | 0% | NS |
| 53 | 2.0% | 2.9% | NS |
| 54 | 0 % | 0% | NS |
| 55 | 4.0% | 2.9% | NS |
| 56 | 1.0% | 1.4% | NS |
| 57 | 8.5% | 2.9% | NS |
| 58 | 3.0% | 4.3% | NS |
| 60 | 3.5% | 2.9% | NS |
| 61 | 0.5% | 0 % | NS |
| 62 | 6.0% | 8.7% | NS |
| 63 | 1.0% | 1.4% | NS |
| 64 | 0 % | 0 % | NS |
| 65 | 1.5% | 4.3% | NS |
| 70 | 0 % | 0 % | NS |
| 71 | 0 % | 0 % | NS |
| 72 | 0 % | 0 % | NS |
| 73 | 0.5% | 0 % | NS |
| 75 | 0.5% | 0 % | NS |
| 76 | 0 % | 0 % | NS |
| 77 | 0 % | 0 % | NS |
| (b) Continued. | |||
| HLA-Cw | Control group | CIU AICU group | P |
| (phenotype carrier) | (n = 200) | (n = 69) | |
| 1 | 9.0% | 5.8% | NS |
| 2 | 8.5% | 11.6% | NS |
| 3 | 16.0% | 8.7% | NS |
| 4 | 37.0% | 14.5% | .001 |
| 5 | 5.5% | 14.5% | .016 |
| 6 | 17.5% | 8.7% | NS |
| 7 | 48.5% | 23.2% | < .001 |
| 8 | 0 % | 1.4% | NS |
| 17 | 1.0% | 0 % | NS |
| (c) | |||
| HLA-DRB1* | Control group | CIU AICU group | P |
| (allele carrier) | (n = 200) | (n = 69) | |
| 1 | 16.0% | 15.9% | NS |
| 3 | 21.0% | 14.5% | NS |
| 4 | 15.5% | 10.1% | NS |
| 7 | 24.0% | 26.1% | NS |
| 8 | 7.5% | 4.3% | NS |
| 9 | 1.0% | 0 % | NS |
| 10 | 3.5% | 0 % | NS |
| 11 | 39.5% | 44.9% | NS |
| 12 | 6.5% | 4.3% | NS |
| 13 | 22.0% | 26.1% | NS |
| 14 | 7.5% | 11.6% | NS |
| 15 | 15.5% | 8.7% | NS |
| 16 | 12.0% | 8.7% | NS |
| 17 | 1.0% | 0 % | NS |
| (d) | |||
* By χ2 test or Fisher's exact test; NS: not significant.